Results 171 to 180 of about 142,539 (313)

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster, J. M. P. A. van den Reek, E. M. G. J. de Jong, S. van Beugen, A. I. M. van Laarhoven, I. Haeck, M. de Bruin‐Weller, M. L. Schuttelaar, B. Horvath, A. Gostyński, A. Knulst, M. H. Vermeer, L. Nguyen, L. Gerbens, P. Spuls, M. A. Middelkamp‐Hup, V. Exadaktylos, T. Niemeyer‐van der Kolk, A. R. Schrader, A. M. Sluijmers, J. Versteeg, B. W. M. Arents, I. van Ee, J. L. A. G. van der Zon, M. de Leeuw, T. de Leeuw, P. van den Broek, C. Berkhof, D. Vellinga, S. Weidinger, S. Dubrac, Y. Li, M. van Steensel, M. Marchetti‐Deschmann, M. Maurer, H. van der Zee, J. Damman, D. J. Hijnen, F. Wijk, M. M. B. Seyger, H. Röckmann, D. M. W. Balak, M. B. A. van Doorn, R. Rissmann, The Next Generation ImmunoDermatology (NGID) consortium, Rob Vreeken, Eva Cuypers, Boudewijn Lelieveldt, Abdoel El Ghalbzouri, Hanna Niehues, Ellen van den Bogaard, Tom Ederveen, Els van der Pool, Nanda Olde, Debra Trampe, Ellen Stijl‐’t Hart, Lisanne Wezendonk, Johan Westerhuis, Huma Shehwana, Joerg Schreiber, Jeremy Bost, Mie Bech Lukassen, Jimmy Bakker, Juliette Simons, Fauve van den Berge, Colin Spence, Elise Beljaards, Anastasiia Myronenko, Mariona Oliver   +68 more
wiley   +1 more source

Severe Adult HLH/MAS With SPTCL-Like Panniculitis: A Phenotype-Guided, Resource-Adapted Therapeutic Strategy Without Cytotoxic Therapy. [PDF]

Clin Case Rep
Taha HM, Marouf O, Taha KH.
europepmc   +1 more source

Pediatric Hepatology: A three-year experience with pediatric liver transplantation with cyclosporine and steroids [PDF]

, 1986
Gartner, JC, Iwatsuki, S, Malatack, JJ, Shaw, BW, Starzl, TE, Urbach, AH, Zitelli, BH   +6 more
core  

Mapping malignant T‐cell states and immune circuits in Sézary syndrome by single‐cell analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Peripheral blood single‐cell RNA‐seq from leukaemic CTCL defined three malignant T‐cell programmes: MTC CM, MTC Reg and MTC E/EM, each with distinct features and candidate vulnerabilities. For example, inferred immune circuits highlighted actionable IL‐10/JAK–TYK2–STAT3 signalling, KIR–MHC I inhibitory interactions and myeloid/B‐cell inflammatory and ...
Beth A. Childs, Eslam A. Elghonaimy, Praveen Ramakrishnan Geethakumari, Kiran A. Kumar, Joseph F. Merola, Heather W. Goff, Todd A. Aguilera   +6 more
wiley   +1 more source

Some of the Newest Therapeutic Methods in Canine Atopic Dermatitis. [PDF]

Vet Sci
Mazilu CC, Strichea AH, Solcan G.
europepmc   +1 more source

Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Systematic review (51 studies; 547 patients) indicates dupilumab may unmask/worsen CTCL (mainly MF/SS). A French Delphi consensus recommends rigorous diagnostic workup, avoiding dupilumab in confirmed CTCL, discontinuing upon diagnosis, and favouring methotrexate or phototherapy.
Florent Amatore, Madeleine Neildez, Adèle de Masson, Maxime Battistella, Marie Tauber, Saskia Ingen‐Housz‐Oro, Catherine Droitcourt, Delphine Staumont‐Sallé, Marie Beylot‐Barry   +8 more
wiley   +1 more source

Kawasaki Disease in a Child With Trisomy 18 Treated With Initial Combination Therapy, Including Cyclosporine. [PDF]

Case Rep Pediatr
Sahara Y, Yagi N, Watanabe Y, Aoki K, Iwaku T, Tominaga M, Ikeda H.   +6 more
europepmc   +1 more source

Effective Management of Recalcitrant Hailey–Hailey Disease With Risankizumab

International Journal of Dermatology, EarlyView.
Joy Justice, Adriana Della Porta, Eva Niklinska, Jami L. Miller   +3 more
wiley   +1 more source

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This multicentre, observational cohort study in adults and adolescents with atopic dermatitis found that dupilumab treatment provides a higher probability of achieving the treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4 compared with tralokinumab treatment. Absolute EASI and NRS‐pruritus differences were small among responders.
Lian F. van der Gang, Nicolaas P. A. Zuithoff, Inge M. Haeck, Veroniek E. M. Harbers, Simone Stadhouders‐Keet, Klaziena Politiek, Albert J. Oosting, Anneke M. T. van Lynden‐van Nes, Hoo‐Yin Lam, Anne‐Moon van Tuyll van Serooskerken, Shiarra M. Stewart, Antoni Gostynski, Annebeth Flinterman, Berit Velstra, Wouter R. H. Touwslager, Francine C. van Erp, Marie L. A. Schuttelaar, Marjolein S. de Bruin‐Weller, Marlies de Graaf   +18 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source